Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07154615 · ClinicalTrials.gov registry record
Assessing Immune Dysfunction in Sepsis
A clinical trial of Sepsis, sponsored by University of Minnesota.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT07154615 is a study of Sepsis that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 150 participants, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07154615, a study of Sepsis, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the \~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.
Conditions Studied
Interventions
- OTHER Observational Only
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2028-11-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07154615
The ClinicalTrials.gov registry entry for NCT07154615 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Observational Only is the first listed.
NCT07154615 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT07154615 about?
NCT07154615 is a clinical study titled "Assessing Immune Dysfunction in Sepsis". Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the \~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective...
What is the current status of trial NCT07154615?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2026-03-01. Estimated completion is 2028-11-01.
What conditions does trial NCT07154615 study?
This clinical trial studies the following conditions: Sepsis.
What interventions are being tested in trial NCT07154615?
The interventions under investigation include: Observational Only (OTHER).
Who is sponsoring clinical trial NCT07154615?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07154615 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.